Immunocore Q1 2026 Results: Strong Growth, Landmark Clinical Data, and Expanding Pipeline

Key Highlights from Q1 2026

• Record KIMMTRAK® Sales: Q1 2026 net sales reached \$106.7 million, up 13.6% year-over-year, driven by growth in the US and Europe.
• Landmark 5-Year Overall Survival Data: KIMMTRAK doubled the likelihood of five-year survival in metastatic uveal melanoma, with data presented at AACR 2026.
• Strong Financial Position: Cash, cash equivalents, and marketable securities totaled \$844.9 million as of March 31, 2026.
• Pipeline Progress: Multiple late-stage trials ongoing in both oncology and infectious disease, with pivotal Phase 3 readouts and new trial initiations expected in 2026.
• Profitability: Net income for Q1 2026 was \$13.0 million, more than double the \$5.0 million reported a year earlier.

Detailed Financial and Operational Review

Commercial Performance

Immunocore delivered another quarter of robust commercial execution, with KIMMTRAK® (tebentafusp) generating \$106.7 million in net revenues. US sales grew 19.1% to \$67.4 million, while Europe contributed \$34.4 million (up 4.9%) and international regions \$4.8 million. The increase was attributed to higher product volumes and new market launches. KIMMTRAK is now approved in 39 countries and commercially launched in over 30 countries, solidifying its position as the standard of care for HLA-A*02:01-positive unresectable or metastatic uveal melanoma (mUM).

Clinical Breakthrough: Five-Year Survival Data

Potentially the most price-sensitive and share-moving news is the presentation of new five-year overall survival (OS) data from the landmark Phase 3 trial of KIMMTRAK at the American Association for Cancer Research (AACR) meeting. In a study of 378 patients with unresectable or metastatic uveal melanoma:

• KIMMTRAK doubled the five-year OS rate (16%) compared to the control arm (8%), with a hazard ratio (HR) of 0.67.
• Median OS was 21.6 months for KIMMTRAK versus 16.9 months for the control.
• The survival benefit was consistent regardless of poor prognostic factors (such as high tumor burden or elevated LDH) or tumor location, and was also evident in patients with progressive disease as best response.
• Importantly, nearly half (44%) of KIMMTRAK long-term survivors received only KIMMTRAK, while 86% of surviving control-arm patients had subsequently crossed over to receive KIMMTRAK, underscoring the drug’s direct benefit.

This is the longest OS follow-up ever reported for a T cell engager in a solid tumor and solidifies KIMMTRAK’s position as a transformative therapy in mUM.

Pipeline and R&D Updates

• 2L+ Advanced Cutaneous Melanoma:
  The pivotal Phase 3 TEBE-AM trial is enrolling patients and expected to complete enrollment in 1H 2026, with topline data anticipated as early as 2H 2026. This study includes tebentafusp monotherapy, combination with pembrolizumab, and a control arm. The company sees a market opportunity of up to 4,000 previously treated HLA-A*02:01-positive patients in this setting.
• Adjuvant Uveal Melanoma:
  The EORTC-sponsored ATOM Phase 3 trial is ongoing in high-risk patients. The target population is up to 1,200 patients in the US and Europe.
• PRAME Portfolio:
  The lead candidate, brenetafusp, is in a registrational Phase 3 (PRISM-MEL-301) trial in first-line advanced cutaneous melanoma (in combination with nivolumab). The company estimates up to 10,000 HLA-A*02:01-positive patients could benefit in the US and Europe. Additional Phase 1/2 trials for brenetafusp and IMC-P115C are ongoing in ovarian cancer, NSCLC, and other solid tumors, with data expected in 2H 2026.
• Infectious Disease and Autoimmune Programs:
  Enrollment is ongoing in a Phase 1/2 trial of IMC-M113V for HIV, aiming for a ‘functional cure.’ Additional data is expected in 2H 2026. The company also expects to initiate a first-in-human trial for IMC-S118AI (type 1 diabetes) and file an IND for IMC-U120AI (dermatological diseases) in 2026.

Financial Performance

• Total Revenue: \$106.7 million (Q1 2026), up from \$93.9 million (Q1 2025).
• Net Income: \$13.0 million, up from \$5.0 million in Q1 2025.
• Diluted EPS: \$0.25 per share (Q1 2026) vs \$0.10 (Q1 2025).
• R&D Expenses: \$61.1 million (Q1 2026), up from \$56.5 million as the company advances its Phase 3 pipeline.
• SG&A Expenses: \$37.9 million, down from \$40.2 million due to increased share-based compensation forfeitures.
• Cash Position: \$845 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing strong runway for ongoing and future trials.

Upcoming Catalysts for Investors

• Topline data from pivotal trials (TEBE-AM, PRISM-MEL-301, ATOM) expected in 2H 2026 and 2027.
• Phase 1/2 data readouts for PRAME and infectious disease programs in 2H 2026.
• Initiation of new clinical trials in autoimmune diseases in 2026.
• Potential for label expansions and increased KIMMTRAK sales as new indications and geographies are accessed.

Risk Factors and Shareholder Considerations

• Clinical and regulatory outcomes for ongoing Phase 3 trials will be critical to the company’s future growth and could significantly impact the share price.
• Any delays or unfavorable safety/efficacy data from pivotal studies, or changes in the competitive landscape, could also affect valuation.
• Macroeconomic and geopolitical risks, including those related to supply chain, inflation, and global conflicts, may impact operations and timelines.
• Significant cash reserves provide a buffer, but continued R&D investment and commercialization expenses are expected.

Conclusion

Immunocore’s Q1 2026 report underscores transformative progress, notably the landmark five-year survival benefit for KIMMTRAK in metastatic uveal melanoma—a result that strongly differentiates the product and should be considered highly price-sensitive. The company is on track for multiple pivotal clinical readouts in late 2026 and 2027, which, if positive, could unlock substantial new markets and further boost revenues. Investors should closely monitor upcoming clinical data, regulatory milestones, and commercial performance for potential share price impacts.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making investment decisions. All forward-looking statements are subject to risks and uncertainties as detailed in Immunocore’s filings with the SEC.

View Immunocore Holdings plc Historical chart here